Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases

This publication has 34 references indexed in Scilit:

• Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice.
  The Journal of Experimental Medicine, 1996
• Interleukin‐12 is required for interferon‐γ production and lethality in lipopolysaccharide‐induced shock in mice
  European Journal of Immunology, 1995
• Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis.
  The Journal of Experimental Medicine, 1995
• In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS).
  The Journal of Experimental Medicine, 1994
• Impaired interleukin 12 production in human immunodeficiency virus-infected patients.
  The Journal of Experimental Medicine, 1994
• IFN-γ Induces IL-12 mRNA Expression by a Murine Macrophage Cell Line, J774
  Biochemical and Biophysical Research Communications, 1994
• Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.
  The Journal of Experimental Medicine, 1994
• Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo
  International Immunology, 1994
• Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.
  The Journal of Experimental Medicine, 1992
• Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.
  The Journal of Experimental Medicine, 1989